HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS)

HC Wainwright reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a report published on Friday, Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock. Separately, StockNews.com lowered shares of Arbutus Biopharma from a buy rating to a hold rating in a research note on […]

Related Keywords

United States ,American , ,York Mellon Corp ,American International Group Inc ,Arbutus Biopharma Corporation ,Jpmorgan Chase Co ,Moneta Group Investment Advisors ,Arbutus Biopharma ,Free Report ,Biopharma Trading Down ,New York Mellon Corp ,Street Group ,Group Investment Advisors ,International Group ,Get Free Report ,Biopharma Corporation ,Arbutus Biopharma Daily ,Nasdaq Abus ,Mabus ,Medical ,Reiterated Rating ,Hc Wainwright ,